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**Abstract**

Among psychiatrists there is a common feeling, that guidelines directives on psychopharmacological treatment are often in contrast to clinical decision making driven by clinical experience. This might be one reason, why compliance to guidelines is not as one might expect.

Reasons for this discrepancy are related among others in the way guidelines are developed by the respective commissions: the experts are often not or not any more clinically experienced, the priority given to meta-analyses lead to relative global results, for more differentiated treatment problems (drug resistence, predominance of certain sub-syndromes, psychiatric and non-psychiatric comorbidity, co-medication etc.) Sufficient data are not available, individual dispositions of the patients are not sufficiently considered in the EBM data base, the gap between phase- studies and phase-4 studies is difficult to overcome.

The current position of EBM neglects extremely the value of clinical practice and is not open enough for more critical reflections about is own methodological limitations. Especially the one-sided preference for meta-analyses should be replaced by a multi-methods approach, involving much more the evaluation of individual studies.This would help among others to give answers also to questions mentioned above, so far mostly not addressed sufficiently by the available guidelines.
